In Vivo Chemoselection with Low Dose Thioguanine
The present disclosure is directed to methods of selecting for modified stem cells in vivo. The present disclosure is also directed to a 6TG dosing schedule. The present disclosure is also directed to an oral formulation comprising 6TG.
1 . A method of increasing an engraftment of genetically modified hematopoietic cells in a human patient following a transplant of the genetically modified hematopoietic cells comprising:
administering to the human patient one or more doses of 6-thioguanine (6TG), wherein an amount of 6TG in each dose of the one or more doses of 6TG ranges from between about 0.2 mg/kg to about 0.6 mg/kg, wherein a total amount of 6TG administered in an administration cycle does not exceed about 7 mg/kg, and wherein a first dose of 6TG is administered to the human patient between about 1 day to about 7 days after the transplant of the genetically modified hematopoietic cells.
2 . The method of claim 1 , wherein the amount of 6TG in each dose of the one or more doses ranges from between about 0.3 mg/kg to about 0.5 mg/kg.
3 . The method of claim 1 , wherein the amount of 6TG in each dose of the one or more doses is about 0.4 mg/kg.
4 . The method of claim 1 , wherein each dose of the one or more doses comprises the same amount of 6TG.
5 . The method of claim 1 , wherein between about 3 and about 10 doses of 6TG are administered to the human patient during the administration cycle.
6 . The method of claim 5 , wherein 4 or 5 doses of 6TG are administered to the human patient during the administration cycle.
7 . The method of claim 5 , wherein the one or more doses of 6TG are spaced apart over equal time periods.
8 . The method of claim 5 , wherein the one or more doses of 6TG are made every third day.
9 . The method of claim 1 , wherein the administration cycle has a duration of about four weeks, and wherein the one or more doses of 6TG are made every third day.
10 . The method of claim 1 , wherein the administration cycle has a duration ranging from between about two weeks to about four weeks, and wherein the one or more doses of 6TG are made every third day.
11 . The method of claim 1 , wherein the first dose of 6TG is administered 2 days after the transplant of the genetically modified hematopoietic cells.
12 . The method of claim 1 , wherein the one or more doses of 6G are administered to the human patient over at least two administration cycles
13 . The method of claim 1 , further comprising measuring an hypoxanthine-guanine phosphoribosyltransferase-enzyme level (HPRT-enzyme level) of the human patient and administering the one or more doses of 6TG based on the measured HPRT-enzyme activity level of the human patient, wherein the amount of 6TG administered in the one or more doses of 6TG is inversely related to the measured HPRT-enzyme activity level.
14 . A method of conferring myeloprotection to a human patient comprising: (i) performing a myelosuppressive conditioning step on the human patient prior to a transplantation of genetically modified hematopoietic cells; and (ii) performing a post-transplantation chemoselection step on the human patient following the transplantation of the genetically modified hematopoietic cells, wherein the post-transplantation chemoselection step comprises administering one or more doses of 6-thioguanine (6TG) to the human patient, wherein an amount of 6TG in each dose of the one or more doses of 6TG ranges from between about 0.3 mg/kg to about 0.5 mg/kg, and wherein a first dose of the one or more doses of 6TG is administered 2 days after the transplantation of the genetically modified hematopoietic cells.
15 . The method of claim 14 , wherein the amount of 6TG in each dose of the one or more doses is about 0.4 mg/kg.
16 . The method of claim 14 , wherein the post-transplantation chemoselection step occurs in an administration cycle having a duration ranging from about 1 week to about 4 weeks, wherein between about 3 and about 10 doses of 6TG are administered during the administration cycle, and wherein a total dose of 6TG administered during the administration cycle does not exceed about 7 mg/kg.
17 . The method of claim 16 , wherein the total dose of 6TG administered during the administration cycle does not exceed about 5 mg/kg.
18 . The method of claim 16 , wherein the total dose of 6TG administered during the administration cycle ranges from between about 2 mg/kg to about 3 mg/kg.
19 . The method of claim 14 , wherein each dose of the one or more doses comprises the same amount of 6TG.
20 . The method of claim 14 , wherein the post-transplantation chemoselection step comprises administering the one or more doses of 6TG over at least two administration cycles.